Context Therapeutics Inc.

Listed Company

CNTXCIK 0001842952NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-36.12M

Total Assets

$68.49M

Equity

$60.47M

Shares Out

91.88M

Op. Cash Flow

$-26.39M

Business

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing T cell engaging (TCE) bispecific antibodies for the treatment of solid tumors. Its main product candidates include CTIM-76 (CLDN6 x CD3), CT-95 (MSLN x CD3), and CT-202 (Nectin-4 x CD3), each designed to redirect T-cell-mediated lysis toward tumor cells expressing the respective target. The company organizes its operations around clinical and preclinical pipeline programs, in‑licensed assets and collaborations, and reliance on third‑party manufacturing and development partners. It pursues worldwide development and commercialization rights and plans distribution through strategic partners and outsourced manufacturing channels in key global markets.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	32	23	18	7	4
General and administrative	8	7	7	8	4
Loss from operations	−40	−30	−25	−15	−11
Interest income	3	3	1	—	—
Other income (expense)	200,471	−1,428	−55,570	—	—
Net loss	−36	−27	−24	−15	−10
Net income (loss) per share - basic (in dollars per share)	−0.38	−0.46	−1.5	−0.93	−3.69
Net income (loss) per share - diluted (in dollars per share)	−0.38	−0.46	−1.5	−0.93	−3.69
Weighted average common shares outstanding - basic (in shares)	95	58	16	16	3
Weighted average common shares outstanding - diluted (in shares)	95	58	16	16	3

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	66	94	14	35	50
Prepaid expenses and other current assets	2	3	2	2	2
Total current assets	68	98	16	38	51
Operating lease right-of-use asset	100,000	218,816	0	51,967	0
Property and equipment, net	29,656	11,959	15,524	27,568	0
Total assets	68	98	16	38	51
Accounts payable	3	1	2	936,330	2
Accrued expenses and other current liabilities	5	1	2	2	1
Operating lease liability - current	112,064	107,316	0	55,078	0
Total current liabilities	8	3	4	3	3
Operating lease liabilities - non-current	0	112,064	0	—	—
Total liabilities	8	3	4	3	3
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding	0	0	0	0	0
Common stock$0.001 par value; 200,000,000 shares authorized; 91,879,177 and 89,704,194 issued and outstanding at December 31, 2025 and December 31, 2024, respectively	91,879	89,704	15,966	15,966	15,966
Additional paid-in capital	191	190	80	79	78
Accumulated deficit	−131	−95	−68	−44	−29
Total stockholders' equity	60	95	12	35	48
Total liabilities and stockholders' equity	68	98	16	38	51

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research And Development Expense, Acquired In Process	2	15	0	—	—
Share-based compensation expense	1	841,867	1	976,440	511,079
Depreciation and amortization expense	16,251	10,881	12,044	9,268	0
Reduction in the carrying amount of operating lease right-of-use asset	108,406	41,822	51,967	78,521	0
Prepaid expenses and other current assets	1	−2	758,829	−736,049	−2
Accounts payable	1	−946,096	1	−787,893	−866,007
Accrued expenses and other current liabilities	4	−619,770	−407,470	1	252,655
Operating lease liability	−107,316	−41,258	−55,078	−75,410	0
Cash used in operating activities	−26	−15	−21	−14	−9
Acquired in-process research and development	−2	−15	0	−500,000	−250,000
Purchase of property and equipment	−33,948	−7,316	0	−36,836	0
Cash used in investing activities	−2	−15	0	−536,836	−250,000
Proceeds from the sale of common stock and prefunded warrants in private placement, net of offering costs	0	95	0	0	29
Payment of offering costs from the sale of common stock from ATM facility	−15,268	0	0	−102,071	−100,000
Proceeds from the sale of common stock from ATM facility, net	0	15	0	—	—
Cash (used in) provided by financing activities	−15,268	109	0	−102,071	58
Net (decrease) increase in cash and cash equivalents	−28	80	−21	−14	49
Cashless exercise of prefunded warrants from private placement	2,175	0	0	345,530	0
Unpaid offering costs in Accounts payable	0	15,268	—	—	—
Right-of-use asset acquired under operating lease	0	260,638	0	130,488	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro